Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (12142)	6/30/2013 6:59:35 AM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (1) \| Respond to of 13111

I understand what they are telling you, or you think they are telling you, but I am confident they will be going for a 'narrow indication' in the classic sense of the phrase..."non-progressing stage III MM" and will not be pursuing the broader 'all stage III and stage IV MM patients" that their competitors are successfully pursuing or have recently achieved. Your claim that the drug 'works great' should simply be evaluated in light of that position the company now finds themselves in. Whenever a new company brings a novel idea to the marketplace of ideas, serious investors look for some form of external validation; a parter, successful award of an SBA or NIH grand in support of the work, primary data published in peer reviewed scientific journals. PVCT has delivered none of these over the years. The reason I am not interesting in attending the share holder meeting is that I know the difference between hype and real science, no amount of popcorn can make that experience more pleasant to sit through. Any company that argues their problems for the past 3 years are related to confusion at the FDA really isn't worth a serious look, you don't need my PhD to understand that.